Amgen On The Offensive Against Roche’s EPO Mircera; Questions Safety Data

Amgen is continuing its offensive against Roche's pending EPO product Mircera by signing an exclusive supply contract with a large dialysis provider and criticizing Roche's clinical trial program for the continuous erythropoietin receptor activator

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet